671 related articles for article (PubMed ID: 27435397)
1. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
Cousin S; Italiano A
Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
[TBL] [Abstract][Full Text] [Related]
2. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
[TBL] [Abstract][Full Text] [Related]
3. Masterful Antibodies: Checkpoint Blockade.
Lonberg N; Korman AJ
Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
Xia Y; Medeiros LJ; Young KH
Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946
[TBL] [Abstract][Full Text] [Related]
5. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
6. Methods to Evaluate the Antitumor Activity of Immune Checkpoint Inhibitors in Preclinical Studies.
Allard B; Allard D; Stagg J
Methods Mol Biol; 2016; 1458():159-77. PubMed ID: 27581021
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitors in Organ Transplant Patients.
Kittai AS; Oldham H; Cetnar J; Taylor M
J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552
[TBL] [Abstract][Full Text] [Related]
8. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
9. The development of immunotherapy in older adults: New treatments, new toxicities?
Helissey C; Vicier C; Champiat S
J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796
[TBL] [Abstract][Full Text] [Related]
10. Erythema nodosum-like panniculitis mimicking disease recurrence: A novel toxicity from immune checkpoint blockade therapy-Report of 2 patients.
Tetzlaff MT; Jazaeri AA; Torres-Cabala CA; Korivi BR; Landon GA; Nagarajan P; Choksi A; Chen L; Uemura M; Aung PP; Diab A; Sharma P; Davies MA; Amaria R; Prieto VG; Curry JL
J Cutan Pathol; 2017 Dec; 44(12):1080-1086. PubMed ID: 28901560
[TBL] [Abstract][Full Text] [Related]
11. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
[TBL] [Abstract][Full Text] [Related]
12. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
13. Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.
Salama AK; Moschos SJ
Ann Oncol; 2017 Jan; 28(1):57-74. PubMed ID: 28177433
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma.
Abou Alaiwi S; Xie W; Nassar AH; Dudani S; Martini D; Bakouny Z; Steinharter JA; Nuzzo PV; Flippot R; Martinez-Chanza N; Wei X; McGregor BA; Kaymakcalan MD; Heng DYC; Bilen MA; Choueiri TK; Harshman LC
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066646
[TBL] [Abstract][Full Text] [Related]
15. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
Pérez-Ruiz E; Etxeberria I; Rodriguez-Ruiz ME; Melero I
Clin Cancer Res; 2017 Sep; 23(18):5326-5328. PubMed ID: 28790118
[TBL] [Abstract][Full Text] [Related]
16. Atypical autoimmune adverse effects with checkpoint blockade therapies.
Friedman CF; Snyder A
Ann Oncol; 2017 Feb; 28(2):206-207. PubMed ID: 27993802
[No Abstract] [Full Text] [Related]
17. Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.
Loo K; Daud AI
Cancer J; 2017; 23(1):3-9. PubMed ID: 28114249
[TBL] [Abstract][Full Text] [Related]
18. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
Weber JS; Postow M; Lao CD; Schadendorf D
Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
[TBL] [Abstract][Full Text] [Related]
19. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis.
Zhang T; Xie J; Arai S; Wang L; Shi X; Shi N; Ma F; Chen S; Huang L; Yang L; Ma W; Zhang B; Han W; Xia J; Chen H; Zhang Y
Oncotarget; 2016 Nov; 7(45):73068-73079. PubMed ID: 27683031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
